Results 1 to 10 of about 96,870 (119)

Impact of Glucose Metabolism Status on the Association between Apolipoprotein A-I and Ischemic Risk in Patients with Coronary Artery Disease: A Large-Sample Cohort Study [PDF]

open access: yesEndocrinology and Metabolism
Background Apolipoprotein A-I (ApoA-I) is a key cardioprotective lipoprotein. Nevertheless, it remains unclear how ApoA-I relates to ischemic risk across glucose metabolism statuses in patients with coronary artery disease (CAD).
Kailun Yan   +10 more
doaj   +2 more sources

The apolipoprotein B and apolipoprotein A-I Ratio serves as a strong prognostic factor for the overall survival of patients with colorectal cancer

open access: yesFrontiers in Oncology, 2023
BackgroundThe lipid metabolism status of patients with colorectal cancer (CRC) has not been understood comprehensively. The present study investigated the characteristics of lipid metabolism parameters in CRC patients with or without metastases and ...
Yangxun Pan   +18 more
doaj   +1 more source

Correlation between Pretreatment Serum Apolipoprotein Level and Prognosis of Small Cell Lung Cancer Patients

open access: yesChinese Journal of Lung Cancer, 2020
Background and objective Lung cancer is the leading cause of cancer-related death, and small cell lung cancer (SCLC) has a poor prognosis in all types of lung cancer.
Ya DONG   +4 more
doaj   +1 more source

Apolipoprotein Mimetic Peptides: A New Approach for the Treatment of Asthma

open access: yesFrontiers in Pharmacology, 2012
New treatments are needed for severe asthmatics to improve disease control and avoid severe toxicities associated with oral corticosteroids. We have used a murine model of house dust mite (HDM)-induced asthma to identify steroid-unresponsive genes that ...
Xianglan eYao   +3 more
doaj   +1 more source

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally[S]

open access: yesJournal of Lipid Research, 2011
To determine if the dose of peptide administered or the plasma level was more important, doses of 0.15, 0.45, 4.5, or 45 mg/kg/day of the peptide D-4F were administered orally or subcutaneously (SQ) to apoliptotein (apo)E null mice.
Mohamad Navab   +6 more
doaj   +1 more source

Hypertriglyceridemia promotes dysfunctions in high-density lipoprotein increasing the cardiovascular risk

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2023
Hypertriglyceridemia is associated with several metabolic diseases. The triglycerides (TG) disrupt the cholesterol reverse transport and contribute to increased levels of low-density lipoprotein (LDL).
Richard Rarison Cavalcante Meneses   +12 more
doaj   +1 more source

Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins

open access: yesJournal of Lipid Research, 2006
Plasma phospholipid transfer protein (PLTP) is a multifaceted protein with diverse biological functions. It has been shown to exist in both active and inactive forms.
Marian C. Cheung, John J. Albers
doaj   +1 more source

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids

open access: yesJournal of Lipid Research, 2009
Administered subcutaneously, D-4F or L-4F are equally efficacious, but only D-4F is orally efficacious because of digestion of L-4F by gut proteases. Orally administering niclosamide (a chlorinated salicylanilide used as a molluscicide, antihelminthic ...
Mohamad Navab   +8 more
doaj   +1 more source

Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes1

open access: yesJournal of Lipid Research, 2006
Plasma cholesteryl ester transfer protein (CETP) has a profound effect on neutral lipid transfers between HDLs and apolipoprotein B (apoB)-containing lipoproteins when it is expressed in combination with human apoA-I in HuAI/CETP transgenic (Tg) rodents.
David Masson   +8 more
doaj   +1 more source

Alteration of plasma HDL cholesteryl ester composition with transgenic expression of a point mutation (E149A) of human LCAT

open access: yesJournal of Lipid Research, 2001
We have previously identified a single amino acid mutation (hE149A) in human LCAT that increases its in vitro reactivity with phosphatidylcholine species containing sn-2 arachidonate (Wang et al. 1997. J. Biol. Chem. 272: 280–286).
James W. Furbee, Jr.   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy